Open access · CC-BY
via OpenAlex
A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures
Olivier Govaere, Megan Hasoon, Leigh Alexander, Simon Cockell, Dina Tiniakos, Mattias Ekstedt, Jörn M. Schattenberg, Jérôme Boursier, Elisabetta Bugianesi, Vlad Ratziu, LITMUS Investigators, Ann K. Daly, Quentin M. Anstee
Nature Metabolism · 2023 · ▲ 155 citations
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a common, progressive liver disease strongly associated with the metabolic syndrome. It is unclear how progression of NAFLD towards cirrhosis translates into systematic changes in circulating proteins. Here, we provide a detailed proteo-transcriptomic map of steatohepatitis and fibrosis during progressive NAFLD. In this multicentre proteomic study, we characterize 4,730 circulating proteins in 306 patients with histologically characterized NAFLD and integrate this with transcriptomic analysis in paired liver tissue. We identify circulating proteomic signatures for active steatohepatitis and advanced fibrosis, and correlate these with hepatic transcriptomics to develop a proteo-transcriptomic signature of 31 markers. Deconvolution of this signature by single-cell RNA sequencing reveals the hepatic cell types likely to contribute to proteomic changes with disease progression. As an exemplar of use as a non-invasive diagnostic, logistic regression establishes a composite model comprising four proteins (ADAMTSL2, AKR1B10, CFHR4 and TREM2), body mass index and type 2 diabetes mellitus status, to identify at-risk steatohepatitis.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/s42255-023-00775-1
- Canonical
- link ↗
- Fetched
- 2026-07-25 MST
Cite this
APA
Govaere, O., Hasoon, M., Alexander, L., Cockell, S., Tiniakos, D., Ekstedt, M., Schattenberg, J.M., Boursier, J., Bugianesi, E., Ratziu, V., Investigators, L., Daly, A.K., & Anstee, Q.M. (2023). A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures. <em>Nature Metabolism</em>. https://doi.org/10.1038/s42255-023-00775-1
Vancouver
Govaere O, Hasoon M, Alexander L, Cockell S, Tiniakos D, Ekstedt M, et al. A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures. Nature Metabolism. 2023. doi:10.1038/s42255-023-00775-1.
BibTeX
@article{olivier2023Aprote,
title = {A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures},
author = {Olivier Govaere and Megan Hasoon and Leigh Alexander and Simon Cockell and Dina Tiniakos and Mattias Ekstedt and Jörn M. Schattenberg and Jérôme Boursier and Elisabetta Bugianesi and Vlad Ratziu and LITMUS Investigators and Ann K. Daly and Quentin M. Anstee},
journal = {Nature Metabolism},
year = {2023},
doi = {10.1038/s42255-023-00775-1},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Biomedicines 2022
Open access · CC-BY
The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC
Molecular and Cellular Endocrinology 2016
Preprint · OA
Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging
International Journal of Molecular Sciences 2016
Open access · CC-BY
Telomeres, NAFLD and Chronic Liver Disease
Clinical and Molecular Hepatology 2022
Open access · CC-BY
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
Molecular & Cellular Proteomics 2022
Open access · OA
Integrated Liver and Plasma Proteomics in Obese Mice Reveals Complex Metabolic Regulation
Cell Communication and Signaling 2021
Open access · CC-BY